Cancer Immunome Atlas

Cancer Immunome Atlas
Name	Cancer Immunome Atlas
Type	Resource
Focus	Cancer immunogenomics
Creator	Translational research groups
Country	International

Cancer Immunome Atlas is an integrated resource that compiles immunogenomic profiles across malignancies to map interactions among tumor cells, immune infiltrates, and microenvironmental factors. It aggregates high-throughput sequencing, expression, and clinical annotation to support comparative analyses, biomarker discovery, and translational oncology efforts. The Atlas serves investigators in precision oncology, immunotherapy development, and systems biology.

Overview

The project synthesizes datasets from initiatives such as The Cancer Genome Atlas, International Cancer Genome Consortium, European Bioinformatics Institute, National Cancer Institute, and Genome Research Limited partners to create harmonized immunogenomic maps. It links tumor-intrinsic features to immune phenotypes using methods influenced by work at Broad Institute, Wellcome Sanger Institute, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, and Fred Hutchinson Cancer Center. The resource supports cross-referencing with clinical trials cataloged by ClinicalTrials.gov, registries maintained by European Medicines Agency, and outcome repositories curated by American Society of Clinical Oncology.

Data Sources and Methodology

Data ingestion integrates raw and processed inputs from sequencing centers like Illumina, Oxford Nanopore Technologies, and PacBio as well as expression platforms from Affymetrix and Thermo Fisher Scientific. Clinical annotations derive from hospital systems such as Mayo Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, Cleveland Clinic, and multicenter consortia including Stand Up To Cancer and AACR Project GENIE. Bioinformatic pipelines adapt algorithms from groups at European Molecular Biology Laboratory, Cold Spring Harbor Laboratory, Stanford University School of Medicine, and Harvard Medical School for somatic mutation calling, HLA typing, neoantigen prediction, and immune deconvolution. Statistical frameworks reference methods developed at University of California, San Francisco, Johns Hopkins University, University of Toronto, Karolinska Institutet, and McGill University.

Components and Features

Core modules encompass somatic variant catalogs, neoantigen prediction suites, immune cell fraction estimates, and checkpoint expression matrices, with visualization tools modeled after portals from cBioPortal, UCSC Genome Browser, Ensembl, Gene Expression Omnibus, and ArrayExpress. Immunophenotyping leverages deconvolution methods inspired by work at Harvard T.H. Chan School of Public Health, University of Oxford, University of Heidelberg, University College London, and Yale School of Medicine. The Atlas includes curated antigen lists informed by research from Peter Doherty Institute, Salk Institute, and vaccine groups at Bill & Melinda Gates Foundation-supported centers. Interactive APIs are patterned after services from Amazon Web Services, Google Cloud Platform, and Microsoft Azure for scalable compute and data sharing, with governance referencing policies from National Institutes of Health, European Commission, and World Health Organization.

Applications in Research and Clinical Practice

Investigators apply the Atlas to prioritize neoantigens for therapeutic vaccines, a strategy pursued at institutions like National Cancer Center Hospital, Weill Cornell Medicine, and Karolinska University Hospital. It supports biomarker discovery for immune checkpoint blockade therapies developed by companies such as Bristol Myers Squibb, Merck & Co., Roche, and Novartis and informs trial designs registered with National Comprehensive Cancer Network guidelines and consulted by European Society for Medical Oncology. Translational projects couple Atlas-derived signatures with single-cell sequencing efforts at 10x Genomics, spatial transcriptomics from NanoString Technologies, and multiplex imaging platforms used at German Cancer Research Center and Fred Hutchinson Cancer Center. Health technology assessment groups like Institute for Clinical and Economic Review utilize aggregated evidence for value assessment.

Limitations and Challenges

Biases arise from cohort composition linked to contributing centers including Stanford Hospital, Mount Sinai Health System, UCLA Health, University of Chicago Medical Center, and UCSF Medical Center that may underrepresent populations served by World Health Organization-listed regions. Technical heterogeneity across platforms from Illumina and Affymetrix and disparate clinical coding standards such as those promulgated by Centers for Medicare & Medicaid Services and National Health Service (England) complicate harmonization. Ethical and legal concerns reference frameworks from Belmont Report, data protection regimes like General Data Protection Regulation, and consent models advocated by Council for International Organizations of Medical Sciences. Computational reproducibility challenges engage developer communities at GitHub, Bioconductor, and Docker registries.

Future Directions

Planned expansions aim to integrate longitudinal sampling from longitudinal cohorts at Framingham Heart Study-style consortia, enhanced linkage with proteomic datasets from Human Protein Atlas efforts, and tighter interoperability with clinical decision support systems implemented at Epic Systems Corporation and Cerner Corporation. Advances will likely incorporate multimodal single-cell modalities popularized by Broad Single Cell Portal collaborations and federated learning approaches promoted by Federated AI community and initiatives supported by Horizon Europe. Governance updates may align with international standards from International Committee of Medical Journal Editors and ethics guidance from UNESCO.

Category:Cancer research